Keyphrases
Adverse Effects
18%
Afatinib
12%
Asthma
32%
Autoimmune Hemolytic Anemia
12%
Carboplatin
15%
Chemotherapy
46%
Chest CT
15%
Chest Pain
13%
Chest Radiograph
19%
Chronic Obstructive Pulmonary Disease
16%
Chronic Pulmonary Aspergillosis
16%
Cisplatin
15%
Clinical Course
25%
Clinical Parameters
12%
Confidence Interval
14%
Egfr
16%
EGFR mutation
16%
Elderly Patients
16%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
33%
Immune Checkpoint Inhibitor Therapy
26%
Immune Checkpoint Inhibitors
33%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
14%
Lung Adenocarcinoma
25%
Lung Cancer
93%
Metastasis
18%
Monotherapy
39%
Non-small Cell Lung Cancer (NSCLC)
100%
Older Men
35%
Older Women
12%
Organizing Pneumonia
12%
Osimertinib
14%
Overall Survival
12%
Pathological Findings
16%
Patient Characteristics
12%
Pembrolizumab
12%
Performance Status
15%
Pleural Effusion
22%
Prednisolone
15%
Prognostic Factors
18%
Programmed Death-ligand 1 (PD-L1)
19%
Programmed Death-ligand 1 Expression
16%
Progression-free Survival
42%
Pulmonary Sarcomatoid Carcinoma
12%
Rheumatoid Arthritis
16%
Sirtuin 1 (SIRT1)
22%
Small Cell Carcinoma
12%
Small Cell Lung Cancer
33%
SRT1720
16%
Tumor
21%
Tumor Cells
14%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
25%
Amrubicin
8%
Asthma
24%
Bone Lesion
8%
Breast Cancer
8%
Carcinoma
8%
Carnitine
8%
Chemotherapy
61%
Chronic Obstructive Lung Disease
17%
Cisplatin
15%
Creatinine
8%
Cystatin C
8%
Disease
14%
Disease Course
13%
Disease Exacerbation
11%
Eaton Lambert Syndrome
8%
Epidermal Growth Factor Receptor
45%
Epidermal Growth Factor Receptor Kinase Inhibitor
30%
Etanercept
8%
Hydrocortisone
8%
Immune Checkpoint Inhibitor
34%
Inflammation
10%
Inflammatory Arthritis
16%
Irinotecan
8%
Lactate Dehydrogenase
13%
Loss of Appetite
8%
Lung Cancer
47%
Lung Tuberculosis
8%
Messenger RNA
10%
Monotherapy
38%
Mouse Model
8%
N [2 [3 (1 piperazinylmethyl)imidazo[2,1 B]thiazol 6 Yl]phenyl] 2 Quinoxalinecarboxamide
16%
Neoplasm
27%
Non Small Cell Lung Cancer
68%
Organizing Pneumonia
8%
Osimertinib
14%
Ovalbumin
8%
Overall Survival
22%
Pembrolizumab
9%
Pemetrexed
8%
Programmed Death 1 Ligand 1
28%
Progression Free Survival
37%
Recurrent Disease
12%
Retrospective Study
40%
Rheumatoid Arthritis
16%
Sirtuin 1
8%
Small Cell Lung Cancer
44%
Squamous Cell Lung Carcinoma
8%
Tuberculous Pleurisy
8%
Wheezing
8%
Medicine and Dentistry
Adenocarcinoma
10%
Adverse Event
13%
Asthma
15%
Breast Cancer
12%
Carboplatin
14%
Chemotherapy
48%
Chest Radiograph
9%
Chronic Obstructive Pulmonary Disease
9%
Comorbidity
9%
Coughing
9%
Desmopressin
9%
Diabetes Insipidus
10%
Disease
12%
Disease Course
25%
Disease Exacerbation
9%
Epidermal Growth Factor Receptor
17%
Epidermal Growth Factor Receptor Kinase Inhibitor
13%
Erlotinib
9%
Evans Syndrome
12%
Gefitinib
10%
Immune Checkpoint Inhibitor
39%
Lactate Dehydrogenase
9%
Local Therapy
8%
Loss of Appetite
10%
Lung
23%
Lung Adenocarcinoma
25%
Lung Aspergillosis
16%
Lung Cancer
89%
Lung Carcinoma
12%
Meningeal Carcinomatosis
9%
Messenger RNA
9%
Metastatic Carcinoma
27%
Monotherapy
16%
Neoplasm
11%
Non Small Cell Lung Cancer
55%
Overall Survival
11%
Patient Characteristics
10%
Pleura Effusion
22%
Prednisolone
13%
Progression Free Survival
21%
Radiation Therapy
17%
Recurrent Disease
9%
Retrospective Study
27%
Sirtuin1
16%
Small Cell Lung Cancer
28%
Systemic Therapy
10%
T-Helper Cell
10%
Thorax Pain
12%
Thorax Radiography
21%
Tumor Cell
18%
